{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:16:23Z","timestamp":1790964983316,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the benefits and tolerability of TACE combined with second-line regorafenib in patients with unresectable advanced HCC and failure to first-line treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a multicenter retrospective study of patients with progression after first-line sorafenib and\/or lenvatinib between 01\/2019 and 04\/2020 at four tertiary hospitals in China. The patients were treated with TACE. Then, 5\u20137\u00a0days after the first TACE, the patients started taking regorafenib for 3\u00a0weeks every 4-week cycle. The overall survival (OS), time to progression (TTP), progression-free survival (PFS), and adverse events (AEs) were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up was 5.6 (range 0.7, 17.0) months. The median age was 60 (range 35, 79) years. There were 32 (84.2%) males. The patients underwent a median of three TACE sessions (range 1\u201313). The initial doses of regorafenib were 20\u00a0mg\/d (n\u2009=\u20091, 2.6%), 80\u00a0mg\/d (n\u2009=\u200910, 26.3%), 120\u00a0mg\/d (n\u2009=\u200915, 39.5%), and 160\u00a0mg\/d (n\u2009=\u200911, 28.9%). The incidence of grade 3\/4 AEs was 15.8%. Two patients stopped regorafenib due to AEs. The median OS was 14.3\u00a0months. The median PFS and TTP were 9.1 (95% CI 4.0, 14.2) and 9.1 (95% CI 5.5, 12.8) months, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study provides real-world evidence indicating that regorafenib combined with TACE was beneficial and tolerable in patients with unresectable HCC. Additional prospective large-scale studies are required for confirmation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01967-3","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T17:47:54Z","timestamp":1634752074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yue","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinsheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"1967_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hepatobiliary Cancers. Version 5.2020. Fort Washington: National Comprehensive Cancer Network; 2020."},{"key":"1967_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"1967_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1967_CR4","first-page":"121","volume":"2020","author":"M Wu","year":"2019","unstructured":"Wu M, Tang Z, Liu Y, Chen X, Wang X, Sun Y, et al. Guidelines for diagnosis and treatment of primary liver cancer. Zhongguo Shiyong Waike Zazhi. 2019;2020:121\u201338.","journal-title":"Zhongguo Shiyong Waike Zazhi"},{"key":"1967_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"1967_CR6","doi-asserted-by":"crossref","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238\u2013iv55.","DOI":"10.1093\/annonc\/mdy308"},{"key":"1967_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1967_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115\u201332.","journal-title":"CA Cancer J Clin"},{"key":"1967_CR9","doi-asserted-by":"publisher","first-page":"33911","DOI":"10.18632\/oncotarget.15411","volume":"8","author":"JF Jiang","year":"2017","unstructured":"Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget. 2017;8:33911\u201321.","journal-title":"Oncotarget"},{"key":"1967_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/hep.29883","volume":"68","author":"MH Hyun","year":"2018","unstructured":"Hyun MH, Lee YS, Kim JH, Lee CU, Jung YK, Seo YS, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology. 2018;68:977\u201393.","journal-title":"Hepatology"},{"key":"1967_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"1967_CR12","unstructured":"Oncology GWCoCSoC. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of primary Liver Cancer (2018.V1): People's Medical Publishing House; 2018."},{"key":"1967_CR13","first-page":"172","volume":"27","author":"Branch CMDAID","year":"2019","unstructured":"Branch CMDAID. Guidelines for the Clinical Practice of Transcatheter Arterial chemoembolization (TACE) for hepatocellular carcinoma in China. Zhonghua Ganzangbing Zazhi. 2019;27:172\u201381.","journal-title":"Zhonghua Ganzangbing Zazhi"},{"key":"1967_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ejso.2004.10.011","volume":"31","author":"MC Jansen","year":"2005","unstructured":"Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005;31:331\u201347.","journal-title":"Eur J Surg Oncol"},{"key":"1967_CR15","doi-asserted-by":"publisher","first-page":"e100305","DOI":"10.1371\/journal.pone.0100305","volume":"9","author":"L Zhang","year":"2014","unstructured":"Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS ONE. 2014;9:e100305.","journal-title":"PLoS ONE"},{"key":"1967_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"1967_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1967_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1967_CR19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492\u2013501.","journal-title":"Gut"},{"key":"1967_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12885-017-3545-5","volume":"17","author":"FX Wu","year":"2017","unstructured":"Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, et al. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B\/C hepatocellular carcinoma. BMC Cancer. 2017;17:645.","journal-title":"BMC Cancer"},{"key":"1967_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1148\/radiol.13130150","volume":"269","author":"GH Choi","year":"2013","unstructured":"Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603\u201311.","journal-title":"Radiology"},{"key":"1967_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Sch\u00fctz G, et al. Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245\u201355.","journal-title":"Int J Cancer"},{"key":"1967_CR23","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","volume":"12","author":"L Abou-Elkacem","year":"2013","unstructured":"Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, Kiessling F, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013;12:1322\u201331.","journal-title":"Mol Cancer Ther"},{"key":"1967_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"1967_CR25","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","volume":"29","author":"TM Pawlik","year":"2011","unstructured":"Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29:3960\u20137.","journal-title":"J Clin Oncol"},{"key":"1967_CR26","doi-asserted-by":"crossref","unstructured":"Lee MJ, Chang SW, Kim JH, Lee YS, Cho SB, Seo YS, et al. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. Invest New Drugs. 2020.","DOI":"10.1007\/s10637-020-00977-4"},{"key":"1967_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1200\/JCO.2014.60.1153","volume":"33","author":"JJ Knox","year":"2015","unstructured":"Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol. 2015;33:1835\u201344.","journal-title":"J Clin Oncol"},{"key":"1967_CR28","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914\u201321.","journal-title":"Am J Gastroenterol"},{"key":"1967_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14740\/jocmr2496w","volume":"8","author":"K Liu","year":"2016","unstructured":"Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1\u03b1 and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8:297\u2013302.","journal-title":"J Clin Med Res"},{"key":"1967_CR30","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"1967_CR31","doi-asserted-by":"publisher","first-page":"12870","DOI":"10.1038\/s41598-017-12834-1","volume":"7","author":"DS Bai","year":"2017","unstructured":"Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7:12870.","journal-title":"Sci Rep"},{"key":"1967_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.21037\/tgh.2019.06.07","volume":"4","author":"MY Chan","year":"2019","unstructured":"Chan MY, She WH, Dai WC, Tsang SHY, Chok KSH, Chan ACY, et al. Prognostic value of preoperative alpha-fetoprotein (AFP) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in Hong Kong. Transl Gastroenterol Hepatol. 2019;4:52.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1967_CR33","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1002\/cncr.25960","volume":"117","author":"K Uchino","year":"2011","unstructured":"Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475\u201383.","journal-title":"Cancer"},{"key":"1967_CR34","doi-asserted-by":"publisher","first-page":"e0124434","DOI":"10.1371\/journal.pone.0124434","volume":"10","author":"DH Sinn","year":"2015","unstructured":"Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS ONE. 2015;10:e0124434.","journal-title":"PLoS ONE"},{"key":"1967_CR35","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/liv.13107","volume":"36","author":"KM Kim","year":"2016","unstructured":"Kim KM, Sinn DH, Jung SH, Gwak GY, Paik YH, Choi MS, et al. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? Liver Int. 2016;36:1490\u20137.","journal-title":"Liver Int"},{"key":"1967_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1440-1746.2010.06341.x","volume":"26","author":"DJ Yoo","year":"2011","unstructured":"Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY, Yoon HK, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol. 2011;26:145\u201354.","journal-title":"J Gastroenterol Hepatol"},{"key":"1967_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12876-017-0656-z","volume":"17","author":"D Bettinger","year":"2017","unstructured":"Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, Neumann-Haefelin C, et al. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol. 2017;17:98.","journal-title":"BMC Gastroenterol"},{"key":"1967_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1159\/000510798","volume":"9","author":"K Schutte","year":"2020","unstructured":"Schutte K, Schinner R, Fabritius MP, Moller M, Kuhl C, Iezzi R, et al. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer. 2020;9:771\u201386.","journal-title":"Liver Cancer"},{"key":"1967_CR39","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.26586","volume":"58","author":"M Reig","year":"2013","unstructured":"Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013;58:2023\u201331.","journal-title":"Hepatology"},{"key":"1967_CR40","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/hep.27729","volume":"62","author":"M Iavarone","year":"2015","unstructured":"Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology. 2015;62:784\u201391.","journal-title":"Hepatology"},{"key":"1967_CR41","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1440-1746.2011.06917.x","volume":"27","author":"SM Jung","year":"2012","unstructured":"Jung SM, Jang JW, You CR, Yoo SH, Kwon JH, Bae SH, et al. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol. 2012;27:684\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"1967_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.hpb.2016.02.007","volume":"18","author":"U Sarpel","year":"2016","unstructured":"Sarpel U, Spivack JH, Berger Y, Heskel M, Aycart SN, Sweeney R, et al. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. HPB (Oxford). 2016;18:411\u20138.","journal-title":"HPB (Oxford)"},{"key":"1967_CR43","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3748\/wjg.v13.i3.414","volume":"13","author":"K Uka","year":"2007","unstructured":"Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13:414\u201320.","journal-title":"World J Gastroenterol"},{"key":"1967_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000327572","volume":"29","author":"HS Lee","year":"2011","unstructured":"Lee HS. Management of patients with hepatocellular carcinoma and extrahepatic metastasis. Dig Dis. 2011;29:333\u20138.","journal-title":"Dig Dis"},{"key":"1967_CR45","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/liv.14496","volume":"40","author":"C Yoo","year":"2020","unstructured":"Yoo C, Byeon S, Bang Y, Cheon J, Kim JW, Kim JH, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver Int. 2020;40:2263\u201371.","journal-title":"Liver Int"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01967-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T14:24:28Z","timestamp":1635171868000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01967-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1967"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01967-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were performed in accordance with the Declaration of Helsinki. This study was approved by Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20210138). The requirement for individual informed consent was waived by Chinese Ethics Committee of Registering Clinical Trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"393"}}